NCT06830629 Phase 2 Recruiting
A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease Study sponsor: Maze Therapeutics
Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.
Changes Study details Primary completion 2026-09 Estimated
Enrollment · participants 74 Estimated
Source updated 2026-07-27 Last update listed in the registry record
Version history
Changes to this trial Last 12 months
Posted 2026-07-27 · 1 field changed
Planned enrollment increased by 18 participants
− Before 56 participants (planned)
+ After 74 participants (planned)
Check registry source
This database covers selected trials and recorded edits. Some past edits may be missing, and saved text about the main study measures (endpoints) may be shortened. Check the original registry record when a detail matters. Read our methodology